

LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (previously presented) A method of treating a human body for cancer comprising administering an effective therapeutic amount of doxorubicin, in combination with ET-743 in a dose range between 0.6 and 0.75 mg/m² for ET-743, and of about 50 mg/m² or about 60 mg/m² for doxorubicin.
2. (canceled)
3. (previously presented) The method according to claim 1, wherein doxorubicin and ET-743 are provided as separate medicaments for administration at different times.
4. (original) The method according to claim 3, wherein doxorubicin is administered prior to the administration of ET-743.
5. (original) The method according to claim 4, wherein doxorubicin and ET-743 are administered by intravenous injection.
6. (original) The method according to claim 5, wherein the infusion time for intravenous injection is up to 3 hours for doxorubicin and up to 24 hours for ET-743.
7. (original) The method according to claim 6, wherein the infusion time for intravenous

injection is about 1 hour for doxorubicin and about 3 hours for ET-743.

8. (original) The method according to claim 7, where the infusions are carried out at an interval of 1 to 6 weeks.

9. (original) The method according to claim 8, wherein the infusions of both drugs are carried out once every 21 days.

10. (previously presented) The method according to claim 6, wherein the infusion of doxorubicin is carried out on day 1 and the infusion of ET-743 on days 1 and 8, every 21 days.

11. (canceled)

12. (previously presented) The method according to claim 9, wherein doxorubicin is administered in a dosage of about 60 mg/m^2 , followed by ET-743 which is administered in a dosage of 0.7 mg/m^2 .

13. (previously presented) The method according to claim 10, wherein doxorubicin is administered in a dosage of about 50 mg/m^2 , followed by ET-743 which is administered in a dosage of 0.6 mg/m^2 .

14. (previously presented) A method according to claim 1, in which the patient has a cancer selected from sarcoma, osteosarcoma, ovarian cancer, breast cancer, melanoma, colorectal

cancer, mesothelioma, renal cancer, endometrial cancer and lung cancer.

15. (original) A method according to claim 14, in which the patient has a cancer selected from sarcoma, ovarian cancer, endometrial cancer and breast cancer.

16-19. (canceled)